ProteinLogic Appoints Dr Nicolas Huber as Chief Executive Officer

CAMBRIDGE, UK (2018-02-19) – ProteinLogic, the biomarker discovery company, has appointed Dr Nicolas Huber as its Chief Executive Officer.

Dr Huber holds a Masters degree in electronic engineering and a PhD in Space Science from the University of Sussex. After working in the aerospace sector he transitioned to the biomedical sciences, and over the past 8 years has been focused on medical device research and commercialization. Most recently he has developed a new portfolio of devices for the treatment of cancer, and built a product development team and new business line within an established multinational. Dr Huber during this time has also been working with several start-ups in the healthcare sector as a mentor, and providing them guidance on market access and positioning.

“This is a very exciting time to be joining ProteinLogic”, Nicolas commented. “Recent positive developments with the Tuberculosis (TB) diagnostic signature demonstrate that there is a robust and compelling opportunity to realise the medical and commercial vision of the Company. The potential of ProteinLogic’s proprietary immune profiling technology, ImmiPrint®, for the early detection and diagnosis of human diseases is significant.

The most recent analysis and independent validation of multiple samples from a large prospective cohort of TB patients shows that we have achieved, and indeed exceeded, the WHO’s Target Product Profile specifications for a TB rule-out test. This has considerable commercial potential, and the potential to address a healthcare issue of profound global medical significance. The latest data has provided a definitive validation of the Company’s core platform technology, and promises to be the first of many future successes.

My focus as the incoming CEO will be on four key areas, namely: strengthening the Company’s foundations, building a winning team, defining and executing a coherent growth strategy, and ensuring the Company’s long-term financial sustainability.

I am excited to be working with the Board of Directors on making progress on these, and growing ProteinLogic to become a prominent player in the thriving Biotechnology space.”

Mr Peter Klimt, acting Chairman of ProteinLogic, stated: “We are delighted to have Nicolas on-board. His experience in commercialising new medical devices, his understanding of the broader healthcare landscape, and his energy and personality are an excellent addition to ProteinLogic just as the company is entering a phase of intense focus on commercialisation of our proprietary technology. The Board and I are looking forward to working closely with Nicolas to deliver commercial success for our unique diagnostic solutions.”

Further information:


ProteinLogic is a biomarker discovery and exploitation company developing novel diagnostic products that address key unmet medical needs in infection and inflammatory diseases. The first product in the pipeline is a novel diagnostic blood test for tuberculosis. The Company has developed a proprietary biomarker technology (ImmiPrint®) with potential to diagnose early onset of diseases, and to provide information as to how a disease is likely to develop and respond to particular drug treatments. The technology is based upon the profiling of a discrete subset of immune system proteins found in blood and other body fluids.